FindTrial
Sign In

Metronomic Cyclophosphamide

DRUG5 trials

Sponsors

Washington University School of Medicine, Centre Jean Perrin, Heat Biologics, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Besancon

Conditions

GliomaMetastatic Breast CancerNeuroectodermal Tumors, PrimitiveNeuroendocrine TumorsNon Small Cell Lung CancerOsteosarcomaRecurrent Endometrial CancerRetinoblastoma

Phase 1

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
CompletedNCT01661400
Washington University School of MedicineGlioma, Neuroectodermal Tumors, Primitive, Osteosarcoma +4
Start: 2012-10-26End: 2023-12-27Updated: 2024-01-31
Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients
CompletedNCT02755844
Hospices Civils de LyonRecurrent Endometrial Cancer
Start: 2016-09-23End: 2020-06-01Updated: 2026-05-27

Phase 2

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
TerminatedNCT01910870
Centre Jean PerrinMetastatic Breast Cancer
Start: 2013-07-31End: 2016-09-30Updated: 2018-05-18
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
TerminatedNCT02117024
Heat BiologicsNon Small Cell Lung Cancer
Start: 2014-07-31End: 2018-04-30Updated: 2020-02-05
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
CompletedNCT02838342
Centre Hospitalier Universitaire de BesanconNeuroendocrine Tumors
Start: 2015-05-19End: 2021-06-29Updated: 2021-08-02

Related Papers

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial.
2025-02-204 citations
Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.
Journal of Clinical Oncology2024-06-01
Abstract CT005: Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial
Cancer Research2022-06-158 citations
First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial.
Journal of Clinical Oncology2015-05-201 citations